Dykstra: Doubleplay With GE and Sanofi

The stock hasn't been this low in almost four years. It's a Major League company and a great buy at this level. It has $48 billion in operating cash flow and $15 billion in the bank.

I am placing an order to buy 10 January 2009 $22.50 calls (VGEAX) at $8.70 or better.

My second play is Sanofi-Aventis(SNY) today. I'll keep it short and sweet.

Shares of the healthcare research and development company are trading near their lowest point in the last year. The stock closed at $37.17 on Wednesday, just a couple of bucks above the bottom of its 52-week range of $35.06 - $49.04.

It released some bad, but not unexpected news yesterday when it said its cancer drug, Aflibercept, failed to achieve its goal in a recent study. However, I like this company and think it'll pump out a win.

The specifics: I'm going to buy 10 January $30 calls (OYCAF) at $8.20 or better. Don't forget that if either of these orders is filled, I will place a good-till-cancel (GTC) sell order $1.00 above the fill price.

Always Remember: Life is a journey, enjoy the ride!